Literature DB >> 16598305

Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate.

K Ohnishi, F Sakai, S Kudoh, R Ohno.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16598305     DOI： 10.1038/sj.leu.2404207

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  30 in total

1.  A case of chronic myeloid leukemia with eosinophilic interstitial pneumonitis after administration of imatinib mesylate for 11 months.

Authors:  Koichiro Suemori; Hiroshi Fujiwara; Seiichiro Watanabe; Taichi Azuma; Masaki Yasukawa
Journal:  Int J Hematol       Date:  2010-11-26       Impact factor: 2.490

Review 2.  Current status of DILD in molecular targeted therapies.

Authors:  Yoshinobu Saito; Akihiko Gemma
Journal:  Int J Clin Oncol       Date:  2012-11-15       Impact factor: 3.402

Review 3.  Drug-induced interstitial lung disease in molecular targeted therapies: high-resolution CT findings.

Authors:  Fumikazu Sakai; Takeshi Johkoh; Masahiko Kusumoto; Hiroaki Arakawa; Masahiro Takahashi
Journal:  Int J Clin Oncol       Date:  2012-11-10       Impact factor: 3.402

Review 4.  Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

Authors:  Lauren Caldemeyer; Michael Dugan; John Edwards; Luke Akard
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

Review 5.  Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2016-11       Impact factor: 5.606

6.  Interstitial lung disease during targeted therapy in metastatic renal cell carcinoma: a case series from three centres.

Authors:  Philipp Ivanyi; Thomas Fuehner; Meike Adam; Christian Eichelberg; Edwin Herrmann; Axel Stuart Merseburger; Arnold Ganser; Viktor Grünwald
Journal:  Med Oncol       Date:  2014-08-15       Impact factor: 3.064

Review 7.  A Pound of Cure Requires An Ounce (or More) of Prevention: Survivorship and Complications of Therapy for Hematologic Malignancies.

Authors:  Marlise R Luskin; Rahul Banerjee; Sarah Del Percio; Alison W Loren
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

8.  Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate.

Authors:  David A Dorr; Rachel Burdon; Dennis P West; Jennifer Lagman; Christina Georgopoulos; Steven M Belknap; June M McKoy; Benjamin Djulbegovic; Beatrice J Edwards; Sigmund A Weitzman; Simone Boyle; Martin S Tallman; Moshe Talpaz; Oliver Sartor; Charles L Bennett
Journal:  Clin Cancer Res       Date:  2009-05-19       Impact factor: 12.531

Review 9.  Infiltrative lung diseases: complications of novel antineoplastic agents in patients with hematological malignancies.

Authors:  Bobbak Vahid; Paul E Marik
Journal:  Can Respir J       Date:  2008 May-Jun       Impact factor: 2.409

Review 10.  Anticancer therapy and lung injury: molecular mechanisms.

Authors:  Li Li; Henry Mok; Pavan Jhaveri; Mark D Bonnen; Andrew G Sikora; N Tony Eissa; Ritsuko U Komaki; Yohannes T Ghebre
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-23       Impact factor: 4.512
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.